What's Happening?
Cumulus Neuroscience has published a peer-reviewed paper in Scientific Reports detailing a new method for measuring neuroplasticity using a low-burden dry sensor EEG. This method, known as visual evoked potential (VEP) modulation, allows for non-invasive assessment of neuroplasticity, which is crucial for developing treatments for neuropsychiatric and neurodegenerative disorders. The study demonstrated that this approach could be effectively used in real-world clinical trials, offering a scalable and reliable solution for measuring brain function. The research involved deploying the NeuLogiq® Platform in two U.S.-based clinical trials with 50 healthy participants, showing significant improvements in reliability and reduced burden compared to
traditional methods.
Why It's Important?
The development of a scalable and non-invasive method for measuring neuroplasticity is significant for the field of clinical trials, particularly in the context of neuropsychiatric and neurodegenerative disorders. Traditional methods of measuring neuroplasticity are often invasive and burdensome, limiting their use in clinical settings. By providing a reliable and low-burden alternative, Cumulus Neuroscience's method could accelerate the development of new therapies by allowing for more efficient and widespread testing. This advancement could lead to faster drug development processes and more effective treatments, benefiting patients and healthcare providers by improving outcomes and reducing costs.
What's Next?
The successful validation of this neuroplasticity measurement method opens the door for its integration into early-phase CNS drug development. Cumulus Neuroscience plans to further refine and expand the use of this technology in larger cohort studies and multi-site trials. The company aims to provide objective biomarkers of treatment effects and target engagement, which could transform how new therapies are assessed. As the method gains adoption, it may lead to more personalized treatment strategies and better patient stratification in clinical trials, ultimately enhancing the precision and efficacy of new treatments.
